Shares of Medtronic, Inc. (MDT) are higher on the session by 2.32%, trading at $37.02. The company today announced that the U.S. Food and Drug Administration [FDA] has approved its Arctic Front® Cardiac CryoAblation Catheter system, the first and only Cryoballoon in the United States indicated for the treatment of drug refractory paroxysmal atrial fibrillation (PAF).
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!